Artificial Intelligence (AI) in the pharmaceutical industry has transformed from a buzzword to an integral part of daily operations. The potential of AI in pharma is vast, with estimates suggesting it could generate $60 billion to $110 billion in value per year by enhancing efficiencies, speeding up research and development, and delivering critical data insights. This shift is accelerating, with experts predicting that AI’s full potential will be realized by 2030 as more companies adopt these technologies.

As AI tools become more prevalent, they reveal deeper insights that were previously unattainable. For instance, predictive models can now anticipate clinical trial outcomes more accurately, which could reduce the high costs associated with trial failures. Similarly, AI is uncovering how specific genes are expressed in disease progression, providing invaluable data for developing more targeted therapies. However, the success of these AI applications depends on robust digital infrastructure and a strategic approach to implementation.

Unlocking Efficiency with Mareana’s AI Solutions

Mareana’s AI-driven solutions play a key role in this transformation, offering a suite of enterprise AI products designed to accelerate manufacturing, optimize the supply chain, and enhance sustainability efforts. Our Connect™ CPV solution ensures compliance readiness and improves manufacturing yield, while Connect™ CMC and Connect™ VSM automate data analysis and streamline complex supply chain challenges. By integrating these tools, pharma companies can elevate their quality control, achieve compliance readiness, and make informed decisions on sustainability initiatives. Contact us to learn more.

Read the original article here for more insights into AI’s impact on pharma.